NCT04919629
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +29 more
- Locations
-
- Roswell Park Cancer Institute Buffalo, New York, United States
Clinical trial condition
Ovarian Endometrioid Adenocarcinoma
Explore clinical trials studying Ovarian Endometrioid Adenocarcinoma. Study availability and eligibility vary by location and protocol.
42 public trials
2 recruiting studies
Ovarian Endometrioid Adenocarcinoma trial results
NCT04575935
- Conditions
- Adnexal Diseases, Advanced Ovarian Carcinoma, Endocrine Gland Neoplasms, +39 more
- Locations
-
- University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida, United States
- Cleveland Clinic Foundation - Florida Weston, Florida, United States
- Massachusetts General Hospital Boston, Massachusetts, United States
- Dana Farber Cancer Institute Boston, Massachusetts, United States
Active, not recruiting
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
NCT05415709
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +47 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
Active, not recruiting
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT02101775
- Conditions
- Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +33 more
- Locations
-
- City of Hope Comprehensive Cancer Center Duarte, California, United States
- City of Hope South Pasadena South Pasadena, California, United States
- University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
- Decatur Memorial Hospital Decatur, Illinois, United States
Active, not recruiting
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
NCT01116648
- Conditions
- Adnexal Diseases, Breast Diseases, Breast Neoplasms, +21 more
- Locations
-
- Cedars-Sinai Medical Center Los Angeles, California, United States
- University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
- NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois, United States
- Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard Fort Wayne, Indiana, United States
Active, not recruiting
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
NCT02068794
- Conditions
- Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +39 more
- Locations
-
- Mayo Clinic in Rochester Rochester, Minnesota, United States
Active, not recruiting
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03587311
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, +5 more
- Locations
-
- UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
- UCHealth University of Colorado Hospital Aurora, Colorado, United States
- UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida, United States
Active, not recruiting
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02502266
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +29 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- Alaska Women's Cancer Care Anchorage, Alaska, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
Active, not recruiting
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
NCT02142803
- Conditions
- Adnexal Diseases, Adult Glioblastoma, Astrocytoma, +47 more
- Locations
-
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
- Massachusetts General Hospital Charlestown, Massachusetts, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
Active, not recruiting
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT01167712
- Conditions
- Adnexal Diseases, Brenner Tumor, Endocrine System Diseases, +50 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
- Providence Alaska Medical Center Anchorage, Alaska, United States
- Saint Joseph's Hospital and Medical Center Phoenix, Arizona, United States